Environmental and occupational respiratory disordersUpdate on the current status of peptide immunotherapy
Section snippets
Bee venom allergy
Three studies of immunotherapy with peptides derived from the major allergen Api m 1 (phospholipase A2) have been reported. In an open study, 5 subjects with bee venom allergy received divided incremental doses of a mixture of 3 peptides at weekly intervals.13 Patients received 397.1 μg of each of 3 peptides subcutaneously. Patients receiving conventional bee venom immunotherapy were used as controls. After treatment, subcutaneous allergen challenge was tolerated without systemic allergic
References (15)
Peptide therapy for allergic diseases: basic mechanisms and new clinical approaches
Pharmacol Ther
(2005)- et al.
Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats
J Allergy Clin Immunol
(1998) - et al.
The safety and efficacy of ALLERVAX CAT in cat allergic patients
Clin Immunol
(1999) - et al.
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial
Lancet
(2002) - et al.
Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom
J Allergy Clin Immunol
(1998) - et al.
Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial
J Allergy Clin Immunol
(2003) - et al.
Treatment of cat allergy with T-cell reactive peptides
Am J Respir Crit Care Med
(1996)
Cited by (86)
Vaccination against Allergy: A Paradigm Shift?
2020, Trends in Molecular MedicineTreatment with grass allergen peptides improves symptoms of grass pollen–induced allergic rhinoconjunctivitis
2017, Journal of Allergy and Clinical ImmunologyCitation Excerpt :Similarly, a dose of 170 μg of Lolium perenne whole allergen extract, which was hydrolyzed to create peptides, resulted in significant improvement in allergic reactivity in a conjunctival provocation test, whereas neither a lower (70 μg) nor a higher (370 μg) dose was different from placebo.49 The bell-shaped response curve noted in the current study could have been anticipated based on previous evaluations of peptide-based immunotherapies.50 Complete or significant sequence homology exists between MHC class II–binding epitopes in grass allergen peptides and equivalent epitopes from many common grasses, including rye, timothy, Bermuda, orchard, velvet, Kentucky bluegrass, and canary.
Non-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease
2016, Autoimmunity ReviewsInnovative immunotherapies of respiratory allergic diseases
2016, Bulletin de l'Academie Nationale de MedecineSkin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients
2015, Journal of Allergy and Clinical Immunology
Supported by the Canada Research Chairs Programme, the Canadian Foundation for Innovation, and Asthma UK.
Disclosure of potential conflict of interest: M. Larché has consulting arrangements with, owns stock in, and has patent licensing arrangements with Circassia Holdings LTD.